Inion eyes $2m for licensing non-core orthobiologics tech
This article was originally published in Clinica
Anglo-Finnish developer of orthopaedic implants Inion is to gain up to $2m for licensing a non-core bioactive bone growth technology to US company Curative Biosciences. AIM-listed Inion said it had discovered the bioactive properties of N,N-dimethylacetamide (DMA) in promoting bone repair and regrowth throughresearch carried out at its former Cambridge R&D facility. The technology will be licensed for use either alone as a bioactive agent or in resorbable polymer implants, such as plates, membrane and screws. In addition to the $2m in licensing fees and development and sales milestones, Waltham, Massachusetts-based Curative will pay Inion royalties on revenues generated from any products based on this technology.